Objective. Second-trimester sonographic findings of fetal trisomy may include structural abnormalities or sonographic markers of fetal aneuploidy. Unlike structural anomalies, sonographic markers of fetal aneuploidy are insignificant by themselves with regard to outcome, are nonspecific-most frequently seen in normal fetuses, and are often transient. Our objective was to review the secondtrimester sonographic findings of the major trisomic conditions, trisomies 13, 18, and 21. Methods. We reviewed a number of the most commonly accepted markers, including nuchal thickening, hyperechoic bowel, echogenic intracardiac focus, renal pyelectasis, shortened extremities, mild cerebral ventricular dilatation, and choroid plexus cysts. Markers associated with trisomy 21 were emphasized. Results. The sensitivity of sonography for detection of fetal trisomic conditions varies with the type of chromosome abnormality, gestational age at the time of sonography, reasons for referral, criteria for positive sonographic findings, and the quality of the sonography. As an estimate, 1 or more sonographic findings can be identified in approximately 90% of fetuses with trisomy 13, 80% of fetuses with trisomy 18, and 50% to 70% of fetuses with trisomy 21 (Down syndrome). Conclusions. The presence or absence of sonographic markers can substantially modify the risk of fetal Down syndrome and is the basis of the so-called genetic sonogram. Because maternal biochemical and sonographic markers are largely independent, combined risk estimates will result in even higher detection rates than either alone.
reasons for referral, criteria for positive sonographic findings, and the quality of the sonography.
As an estimate, major or structural abnormalities are seen in 20% of fetuses with trisomy 21 (Down syndrome) during the second trimester, whereas they are seen in most fetuses with trisomies 18 and 13. [3] [4] [5] [6] [7] Combined with SMFA, sonographic findings are identified in approximately 50% to 70% of fetuses with Down syndrome, 80% of fetuses with trisomy 18, and 90% of fetuses with trisomy 13. This emphasizes the potential importance of nonstructural markers in detection of fetal trisomy.
In the following sections, we review the second-trimester sonographic findings of the major trisomic conditions, trisomies 13, 18, and 21. We emphasize fetal Down syndrome because it is the most common trisomic condition, the most likely to result in a surviving neonate, and the most likely to show SMFA without structural anomalies.
Trisomy 13
In trisomy 13, malformations of the central nervous system are common. These may include holoprosencephaly, agenesis of the corpus callosum, Dandy-Walker malformation, vermian agenesis, and neural tube defects. Other common malformations detected are facial abnormalities, including cyclopia, hypotelorism, and cleft lip and palate (Fig. 1A) , renal cystic dysplasia or hydronephrosis, cardiovascular malformations, cystic hygroma, polydactyly, and club or rocker-bottom feet.
Markers
Nonspecific markers of trisomy 13 may include mild dilatation of the lateral cerebral ventricles, hyperechoic bowel, and EIF. Lehman et al 6 reported EIF in 39% of fetuses with trisomy 13 before 20 weeks. Multiple EIF probably increase the risk of aneuploidy, including trisomy 13 (Fig. 1B) . The combination of EIF and a hypoplastic-appearing left side of the heart is a characteristic pattern of trisomy 13 (Fig. 2) . 6 We have encountered 1 case of trisomy 13 in which multiple EIF was the only sonographic finding and several other cases in which EIF was the initial finding that led to detection of other subtle anomalies. Because of its association with trisomy 21, EIF is discussed further below (see "Trisomy 21").
Trisomy 18
A wide diversity of sonographic and pathologic abnormalities have been associated with trisomy 18 during the second trimester, including cystic hygroma, nonimmune hydrops, hydrocephalus, spina bifida, diaphragmatic hernia, tracheoesophageal fistula, genitourinary anomalies, cardiovascular malformations, and omphalocele. Subtle abnormalities may include vermian agenesis and 8, 9 small-bowel-containing omphalocele (Fig. 3) , 10, 11 Skeletal abnormalities are common and include clenched hands (Fig.  4) , 12, 13 club feet, and radial aplasia or limb shortening. In the third trimester, some fetuses with trisomy 18 may primarily have intrauterine growth restriction (IUGR), which is often associated with polyhydramnios.
Markers
Subtle or nonstructural findings of trisomy 18 may include choroid plexus cysts, brachycephaly or "strawberry-shaped" head, 14 and single umbilical artery. 15 Of these, choroid plexus cysts (Fig. 5 ) have been the most controversial and the subject of considerable interest. [16] [17] [18] [19] [20] [21] Like other SMFA, choroid plexus cysts are a relatively common variant during the second trimester, are transient, and have no known effect on fetal development. Unlike some of the other potential markers (e.g., nuchal thickening and hyperechoic bowel), choroid plexus cysts have no known association with other adverse outcomes when the karyotype is normal.
Variables that may influence detection of choroid plexus cysts include gestational age, the thoroughness of the sonography, the threshold for calling a finding a choroid plexus cyst, underlying risk factors, and reasons for referral. It should be noted that studies that restrict patients to those with known karyotypes may be biased, because sonographic findings influence patients' decisions about invasive testing. Highrisk patients with SMFA are more likely to undergo invasive testing than low-risk patients with the same findings. For this reason, a higher risk will be found among patients who choose invasive testing compared with patients who do not. Snijders et al 22 reported that among 107 fetuses with isolated choroid plexus cysts who had karyotyping, 2 had chromosome defects (1 each of trisomy 18 and 21), whereas no chromosome abnormality was found among the 174 fetuses 
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with choroid plexus cysts who did not have amniocentesis. Similar results can be found with other SMFA. The prevalence of choroid plexus cysts in the general population has been reported as 0.5% to 3.6%, with most studies reporting in the range of 1% to 2%. 23, 24 At our own center, which has highrisk patients, we observe choroid plexus cysts in approximately 3.5% of fetuses at 14 to 20 weeks. In comparison, choroid plexus cysts are observed in 30% to 40% of fetuses with trisomy 18 before 20 weeks. This might suggest a high risk for trisomy 18 when choroid plexus cysts are identified prenatally. However, because most fetuses with trisomy 18 have other abnormalities, the risk from isolated choroid plexus cysts is relatively low.
Snijders et al 22 observed choroid plexus cysts in 50% of fetuses with trisomy 18 and 1% of karyotypically normal fetuses. They found that isolated choroid plexus cysts carried only a marginally increased risk (likelihood ratio <2) for trisomy 18, but the presence of another abnormality increased the risk approximately 20 times ( Table 2 ). The authors suggested that maternal age should be the main factor in deciding whether to offer fetal karyotyping when isolated choroid plexus cysts are detected. Similar opinions have been reached by a number of other authorities, including Chitty et al, 25 who evaluated 658 fetuses with choroid plexus cysts.
Two meta-analyses found higher likelihood ratios for isolated choroid plexus cysts and trisomy 18 compared with that of Snijders et al. 22 Ghidini and colleagues 26 observed that isolated choroid plexus cysts were detected in 6.7% (13 of 194) of fetuses with trisomy 18 and 0.9% (752 of 79,583) of control fetuses, yielding a likelihood ratio of 7.1. In another report, Yoder et al 27 evaluated 13 prospective studies comprising 246,545 second-trimester scans and found a likelihood ratio of 13.8 for trisomy 18. Despite this relatively high likelihood ratio, the authors concluded that fetal karyotyping should be offered only when maternal age at delivery is 36 years or older or when the risk for trisomy 18 detected by serum multiple-marker screening is more than 1 per 3000.
Among other variables, there is good evidence to suggest that larger choroid plexus cysts further increase the risk of trisomy 18 compared with smaller cysts (Fig. 6) . [28] [29] [30] [31] [32] Such large cysts undoubtedly take longer to resolve, supporting observations that delayed resolution of choroid plexus cysts carries an increased risk for trisomy 18. Whether the cysts are unilateral or bilateral does not appear to be significant, although it is probably true that large cysts also tend to be bilateral.
All of these findings indicate that detection of a choroid plexus cyst, as with any SMFA, should initiate a renewed search for other abnormalities. A choroid plexus cyst can be presumed to be isolated only after a detailed fetal survey fails to show structural abnormalities or other SMFA. As an isolated finding after high-quality sonography, and assuming the patient is otherwise considered at low risk for fetal aneuploidy, we think that detection of choroid plexus cysts should not alter obstetric management. Additional reassurance can be obtained by correlating sonographic findings with serum biochemical markers. 33, 34 Because choroid plexus cysts always resolve, follow-up sonography is of no value in decision making unless it is done to detect other abnormalities that were previously missed (e.g., cardiac defects).
Trisomy 21
Structural or major abnormalities in trisomy 21 include cardiac defects, hydrops, and cystic hygroma. Rarely, duodenal atresia can also be seen before 20 weeks, especially when combined with esophageal atresia. Other abnormalities in this case included a diaphragmatic hernia, a cardiac defect, and probably micrognathia. 39 A slightly higher frequency (21.8%) of structural abnormalities was found in a previous study at our center, but that study included referred patients and also categorized mild ventricular dilatation as a major abnormality for consistency with previous studies. 40, 41 Studies that include patients referred for sonographically detected abnormalities will have a higher rate of major abnormalities.
The low detection rate of structural abnormalities reflects the low sensitivity of sonography for detection of cardiac defects among fetuses with trisomy 21 before 20 weeks. We consistently detect cardiac defects in less than 10% of fetuses with trisomy 21, although the mean gestational age at the time of scanning is 16.9 weeks for these pregnancies. Improved detection of cardiac defects would be expected even a few weeks later. Using nonspecific cardiac findings, such as right-left disproportion, pericardial effusion, and tricuspid regurgitation, DeVore et al 42 reported cardiac findings in 76% of fetuses with trisomy 21, but just 9% had an endocardial cushion defect. The mean gestational age for sonography in that study was also 18 weeks.
A study by Paladini and colleagues 43 suggested what is possible under ideal conditions. Scanning at an optimal gestational age (24 weeks), under optimal conditions (in a dedicated fetal echocardiographic center), with inclusion of subtle ventricular septal defects, and with previous knowledge of fetal karyotype, they were able to detect heart defects in just more than half of fetuses with Down syndrome.
Markers
A large number of potential SMFA have been described in association with trisomy 21 during the second trimester (Table 1) . 40, 41, [44] [45] [46] [47] Among these, we routinely evaluate nuchal thickening, hyperechoic bowel, EIF, shortened limbs, and pyelectasis, because they can be easily sought during the course of routine second-trimester sonography. Other potential markers include a widened pelvic angle, [48] [49] [50] [51] shortened frontal lobes, 52, 53 small ears, 54 clinodactyly, 55 pericardial effusion, and right-left disproportion of the heart, among others. Another potential marker for trisomy 21, although not related to fetal anatomy, is unfused amnion and chorion after 14 weeks. 56 The sensitivities of most sonographic markers are low, particularly compared with that of nuchal translucency in the first trimester (Table 3) . However, the incremental value of each marker improves the overall sensitivity of secondtrimester sonography so that 1 or more markers are observed in more than 50% of fetuses with trisomy 21 at our center. When SMFA are combined with major abnormalities, our overall sensitivity of second-trimester sonography is 69%.
The use of sonographic markers, usually a panel of markers, to modify the risk of fetal Down syndrome is widely referred to as a "genetic sonogram." The actual sensitivity of a genetic sonogram will depend on various factors, including the markers sought, gestational age, reasons for referral, 56A and, of course, the quality of the sonography. Considering these variables and differences in the types of sonographic markers used (Table 4) , the results for genetic sonograms from different centers are surprisingly similar (Table 5 ). Reported detection rates have ranged from 59% to 82%. Detection rates exceeding 90% have even been reported, including a high detection rate for cardiac abnormalities. 42 The risk of fetal trisomy 21 increases dramatically with the number of markers present (Table  6 ). Two or more markers are detected in nearly one third of fetuses with trisomy 21 at our center, compared with less than 2% in normal fetuses. In comparison, a single marker is observed in more than 11% of normal fetuses compared with 22.6% of fetuses with trisomy 21. Similarly, Sohl et al 38 observed a single marker in 14.6% of normal fetuses. On the basis of these data, a single marker increases the risk 2-fold; 2 markers increase the risk nearly 10-fold; and 3 or more markers increase the risk more than 100-fold.
The actual risk will depend on the type as well as the number of markers present. The use of multiple sonographic markers will improve the sensitivity of sonography for detection of fetal Down syndrome but at the cost of a higher false-positive rate if the presence of any single marker is considered a positive finding. This high false-positive rate can understandably lead to considerable anxiety 57 and inconsistent management 58 among low-risk patients. Sonologists should attempt to minimize these false-positive results among low-risk patients but should maximize the sensitivity in high-risk patients.
To optimize clinical management of sonographic markers, Benacerraf and colleagues 40, 41 devised a scoring index in which 2 points are given for structural abnormalities or nuchal thickening and 1 point is given for the other markers. Amniocentesis is offered to those with a score of 2 or greater. This approach avoids the false-positive rates from a single marker, except for nuchal thickening, which is appropriately considered a high-risk marker. The scoring index system can be modified to incorporate maternal age by giving 1 point for women 35 years of age or older and 2 points for women 40 years of age or older (Table 7) . 59 With this modification, a single sonographic marker would be considered a positive result for higher-risk women 35 to 39 years of age, and advanced maternal age alone would be sufficient criteria for women 40 years of age or older. A primary advantage of the scoring index method is that it is easy to use and understand.
Another method of optimizing sonographic findings is to integrate the risk of sonographic markers with the a priori risk based on maternal age. This has been termed "age-adjusted ultrasound risk assessment" (AAURA) for Down syndrome. 45 The sonographic markers are weighted by the strength of individual findings, expressed as likelihood ratios ( Table 7) . The post priori risk is estimated by the likelihood ratios, and the a priori risk is based on maternal age (Table 8) . When AAURA is used, both the sensitivity of fetal Down syndrome and the false-positive rate increase with maternal age. This is appropriate 60 Because sonographic findings appear to be largely independent of both maternal age and biochemical analytes, [61] [62] [63] we think that the risk from biochemical screening (serum markers plus maternal age risk) can be substituted for maternal age risk alone when known.
AAURA, or any method of risk assessment, requires knowledge of the risks associated with individual sonographic markers. In the following sections, individual markers are discussed in greater detail.
Nuchal Thickening
Redundant skin at the back of the neck is a characteristic clinical feature of infants with trisomy 21 and was first reported by Down in 1866. 64 Benacerraf and coworkers [65] [66] [67] first reported the sonographic correlate of this clinical feature in terms of nuchal thickening during the second trimester (Fig. 7) , and thus began the search for other sonographic markers. Nuchal thickening remains one of the most sensitive and important markers of trisomy 21 during the second trimester. Indeed, although other criteria vary among centers, nuchal thickening is universally used as a marker for trisomy 21. Although the sensitivity and false-positive rates will vary with gestational age and the exact criteria for a positive finding, sensitivities in the range of 20% to 40% are most common. On the basis of early experience, Benacerraf et al 65 suggested that a threshold of 6 mm or greater after 15 weeks indicated a high risk of trisomy 21. However, in a subsequent study they observed that none of 303 normal fetuses showed nuchal thickening of greater than 5 mm up to 20 weeks. 66 Several prospective studies have since suggested that 5 mm is a better threshold, which results in improved sensitivity and only a slight increase in the false-positive rate. We have used a 5-mm cutoff for the last 10 years. [68] [69] [70] A number of studies have shown that normal nuchal thickness varies with gestational age, which should not be surprising. This suggests that, as a further refinement, gestational agespecific criteria should be used for increased nuchal thickness rather than a single cutoff. [71] [72] [73] Gestational age-specific criteria may include observed-to-expected or observed-minusexpected nuchal thickness or a comparison of nuchal thickness with other biometric measurements, such as biparietal diameter and femur and humerus length. The use of multiple-of-the-median data, comparing the actual nuchal measurement with the expected measurement, would permit calculation of likelihood ratios and would also permit integration with maternal serum biochemical markers for a combined risk. Bahado-Singh and coworkers have reported multiples of the median and estimated likelihood ratios. 39 Slightly different likelihood ratios were assumed previously in the description of AAURA. 45 
Hyperechoic Bowel
Like other nonstructural markers, hyperechoic bowel is nonspecific and is most commonly observed in normal fetuses. However, it is observed with increased frequency in fetuses with aneuploidy, including trisomy 21 (Fig. 8) . [74] [75] [76] [77] [78] Hyperechoic bowel has also been reported in association with bowel atresia, congenital infection, and, rarely, meconium ileus secondary to cystic fibrosis. 79, 80 An increased risk of IUGR, fetal death, and placenta-related complications is also recognized as being associated with hyperechoic bowel. 81 Despite its subjectivity, the prevalence of hyperechoic bowel among normal fetuses (0.5%) has been remarkably consistent at our center in the last decade and is also similar to that in other reports, suggesting that different centers can agree on the presence of hyperechoic bowel. We use a grading system for hyperechoic bowel, with grade 1 being mildly echogenic and typically diffuse, grade 2 being moderately echogenic and typically focal, and grade 3 being very echogenic, similar to that of bone structures. 82 The echogenicity of normal bowel also increases with transducer frequency, 83 although this effect is uniform, whereas true hyperechoic bowel tends to be focal. To minimize subjectivity, some authors consider only bowel that is markedly hyperechoic, whereas we and others 84, 85 recognize both moderate and markedly hyperechoic bowel (grades 2 and 3) as a risk factor for fetal aneuploidy (Fig. 8) . If only grade 3 hyperechoic bowel were recognized, the sensitivity would be decreased, but the risk (likelihood ratio) would be increased. 
Skeletal Abnormalities
Short stature is a characteristic feature of children with trisomy 21, associated with disproportionately short proximal long bones (femur and humerus). Limb shortening can also be detected in some fetuses with trisomy 21 during the second trimester. [86] [87] [88] [89] [90] [91] However, there is considerable overlap in bone measurements between affected and unaffected fetuses. A shortened humerus appears to be a slightly more specific indicator than a shortened femur. Results probably vary with gestational age, ethnic group, possibly fetal gender, and criteria used, as well as systematic differences in long-bone measurements. 92 Despite these variables, this marker is commonly used at screening centers. The most common method for determination of shortened humerus and femur is comparing the actual measurement with the expected measurement, typically based on biparietal diameter or another dating parameter rather than gestational age. Until now, we have used a single cutoff of 0.91 multiples of the median for a short femur and 0.89 for a short humerus. However, like nuchal measurements, optimal results would be expected by multiple-of-themedian data and corresponding likelihood ratios rather than a single cutoff. 71 These methods are best performed by computer calculations. Other skeletal abnormalities associated with trisomy 21 are clinodactyly (shortened middle phalanx of the fifth finger) and a widened pelvic angle. Although both are well-known clinical features of trisomy 21, these can be difficult to assess on secondtrimester sonography and therefore are not typically included in most screening programs.
Renal Pyelectasis
Mild pyelectasis (hydronephrosis) has been associated with an increased risk of aneuploidy, [93] [94] [95] [96] primarily for trisomy 21. However, it is most commonly seen as a normal variant and appears more commonly in male fetuses. 95 The prevalence of pyelectasis undoubtedly varies with gestational age even during the time of secondtrimester scans (14-22 weeks) . A mild degree of renal pyelectasis may fluctuate during the course of a single examination. Studies are conflicting regarding the possible influence of pyelectasis from maternal hydration as well as the degree of fetal bladder distention. [97] [98] [99] [100] Robinson and colleagues 100 found that the anteroposterior renal pelvic diameter increased with maternal hydration in both normal fetuses and those with pyelectasis and was independent of the state of the fetal bladder, whereas Petrikovsky et al 98 found that the degree of fetal bladder distention was important.
Renal pyelectasis is measured as the fluid-filled renal pelvis in an anteroposterior dimension. We prefer measurement when the kidneys and spine are oriented toward or away from the transducer rather than to the side. The threshold for a positive finding varies among centers, but the most common criteria are greater than 3 to 4 mm. Ideally, gestational age-dependent criteria might be used in the future.
Using a cutoff of greater than 3 mm, we observe pyelectasis in about 3% of normal fetuses at our center. Snijders and Nicolaides 101 estimate that mild pyelectasis increases the risk of trisomy 21 by 1.6-fold over the baseline risk. Our own analysis is consistent with this risk, although this risk may not be increased when pyelectasis is isolated. The lack of association as an isolated finding has also been suggested by other studies, 102, 103 although one center has shown an association as an isolated finding. 104 
Echogenic Intracardiac Foci (or Papillary Muscle Calcification)
Echogenic intracardiac foci as SMFA are the most recent, and probably the most controversial, of the sonographic markers that have been described. It is a common finding during the second trimester, observed in 3% to 4% of normal fetuses. 105, 106 The prevalence appears to be significantly higher among Asian populations; Shipp et al 107 found EIF 3 times more often among Asian patients compared with white patients. That finding is important, because an estimation of risk derived from white populations may not apply to Asian women.
Because EIF is a subjective finding, its detection depends on a variety of factors, including resolution of the sonographic equipment, technique, thoroughness of the examination, and the sonographer's experience. Fetal position is also important, because intracardiac foci are best visualized when the cardiac apex is oriented toward the transducer. 108 Despite these variable factors, similar detection rates of EIF from different studies suggest that experienced sonographers can largely agree on its presence or absence. Like many sonographic markers, it typ-ically resolves by the third trimester despite the outcome. 109 Roberts and Genest 110 were the first to suggest an association between aneuploidy and mineralization of the papillary muscle in a pathologic study. Mineralization of the papillary muscle was observed in 2% of normal fetuses compared with 16% (20 of 126) of those with trisomy 21 and 39% (9 of 23) of those with trisomy 13. Similar but slightly higher rates of EIF have been observed in sonographic studies during the second trimester, possibly because small foci may have escaped pathologic detection.
Comparison of these data, as well as direct correlation by Brown et al, 111 suggests that EIF correlates with papillary muscle mineralization that can be seen histologically.
In 2 sonographic studies of EIF and aneuploidy, Bromley et al 112 detected EIF in 4.7% (62 of 1312) of control fetuses compared with 18% (4 of 22) of those with trisomy 21, and Lehman et al 6 reported EIF in 39% of fetuses with trisomy 13 before 20 weeks. A number of studies have confirmed an association between EIF and trisomy 21 ( Fig. 9) 113-118 with few exceptions. [119] [120] [121] The likelihood ratio of EIF in trisomy 21 has been estimated in the range of 1.8 to 4.2.
The risk of aneuploidy from isolated EIF, as well as other SMFA, may be underestimated among low-risk patients because of incomplete ascertainment. Few patients with an isolated marker undergo chromosome analysis unless they are already considered at high risk. In one of the few studies to address this issue, Simpson and colleagues 114 evaluated 205 fetuses with isolated EIF from low-risk patients. Clinical follow-up was obtained by way of a standard questionnaire completed by the parents when the infants were 6 weeks old. Two infants (1%) proved to have aneuploidy (1 trisomy 21 and 1 unbalanced translocation). On the other hand, the risk of EIF and other markers is probably overestimated in studies in which the fetal karyotype is known for all patients, because sonographic findings influence patient decision making. Many high-risk patients now wait for the results from the second-trimester sonogram before deciding to undergo genetic amniocentesis, and high-risk patients are appropriately more likely to undergo genetic amniocentesis than low-risk patients on the basis of the same sonographic findings. We observed EIF in 5.4% of fetuses with known normal karyotypes compared with 3.9% of all consecutive patients who had normal or presumed normal fetal karyotypes. Previous studies confined to known karyotypes have also shown a higher prevalence of EIF. This emphasizes the potential for bias in studies of sonographic markers that restrict patients to those with known fetal karyotypes.
Multiple or large EIF may be important variables when considering genetic amniocentesis. [122] [123] [124] [125] Bettelheim et al 122 found EIF located in the left ventricle in 96% of cases, in combined left and right ventricles in 4.3%, and isolated to the right ventricle in just 0.7% (1 of 150). Bromley et al 116 concluded that right-sided and bilateral EIF combined together had an approximately 2-fold greater risk of aneuploidy compared with leftsided foci, and others have also found that echogenic foci involving both ventricles are more associated with aneuploidy. Wax and Philput 123 reported that aneuploidy was more common when echogenic foci involved both ventricles compared with either ventricle alone. Vibhakar et al 117 found that of 15 fetuses with multiple EIF, 10 (67%) had abnormal karyotypes, and only 2 of those had other sonographically detected abnormalities besides EIF. More recently, Wax and colleagues 125 correlated an increased risk of aneuploidy with the conspicuity of EIF. Our own observations agree that multiple or unusually prominent EIF appear to carry a greater risk. 
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Mild Ventricular Dilatation
The size of the lateral ventricles remains relatively constant throughout gestation, with a mean diameter of 6.1 ± 1.3 mm and slightly larger ventricles in male than in female fetuses (6.4 versus 5.8 mm). 126 Ventriculomegaly is suspected when the atrial diameter reaches 10 mm, although separation of the dependent choroid from the medial ventricular wall may be visible evidence of early ventricular dilatation. 127 Mild ventricular dilatation deserves comment because it has been associated with trisomy 21 as well as other aneuploidies. [128] [129] [130] Although some authors 40, 41 have categorized it as a major abnormality, we think it shares similar characteristics (nonspecific, common in normal fetuses, and often transient) 131 with other minor markers. It is more likely to be seen as a normal variant later in the second trimester (after 20 weeks) and in male fetuses.
In a series by Bromley et al, 129 12% (5 of 43) of fetuses with mild ventriculomegaly (ventricular diameter, 10-12 mm) had abnormal karyotypes (3 trisomy 21 and 2 trisomy 18), although all of these had other findings. Similarly, in our most recent series of trisomy 21, mild cerebral ventricular dilatation was observed in 4.3% (8 of 186) of affected fetuses, but all had other findings, including structural defects (n = 3), 3 or more minor markers (n = 3), or nuchal thickening alone (n = 2). On the other hand, Pilu et al 130 evaluated 31 fetuses with isolated borderline ventricular dilatation (10-15 mm) and found 3 with aneuploidy (2 with trisomy 21 and 1 with trisomy 13). In a review of the literature including their own cases (n = 234), chromosomal aberrations, mostly trisomy 21, were observed in 3.8%. Vergani et al 132 evaluated 82 cases of mild ventriculomegaly (10-15 mm) and found aneuploidy in 2 cases, both of which were associated with advanced maternal age. Seven additional cases of aneuploidy were associated with other anomalies. Current experience suggests that mild cerebral ventricular dilatation increases the risk for fetal aneuploidy, although this risk remains difficult to determine. Further studies are needed, including studies comparing ventricular measurements of fetuses with trisomy 21 and normal fetuses.
Choroid Plexus Cysts
Although an association between choroid plexus cysts and trisomy 18 has been clearly established, a possible link with trisomy 21 has been controversial. 133 Among 1346 fetuses with isolated choroid plexus cysts reviewed by Yoder et al, 27 5 had trisomy 21. The calculated likelihood ratio for trisomy 21 was 1.87, but this did not reach statistical significance (P = .16). Our own analysis suggests that choroid plexus cysts are statistically more likely in fetuses with trisomy 21 but not as isolated findings. We think that as an isolated finding after high-quality sonography, and assuming the patient is otherwise considered at low risk for fetal aneuploidy, detection of choroid plexus cysts should not alter obstetric management. 100) . To what degree the risk is reduced depends on a variety of factors, including the number and type of criteria used, individual thresholds, and, undoubtedly, the gestational age at the time of scanning. Despite differences among centers, most recent studies (Table 5) suggest that a likelihood ratio in the range of 0.3 to 0.4 can be assigned to a normal sonographic finding. These likelihood ratios correspond to a 60% to 70% reduction of risk. With the use of a larger number of criteria or a higher threshold, sensitivity of sonography approaching 90% has been reported. Vintzileos and colleagues 102 used a large number of SMFA but applied them only to reduce the risk among low-risk patients.
Reduction of Risk in Women Otherwise
Comparison of Sonography and Biochemical Analysis
How does second-trimester sonography compare with second-trimester biochemical screening? Surprisingly little data are currently available regarding this. 62, 135 It appears that the reported sensitivity for sonography in detecting Down syndrome at centers that have high-risk patients is similar to that of second-trimester biochemical screening. Considering the maternal age distribution at the centers with high-risk patients that have reported results, the false-positive results of sonography are also similar to those of biochemical screening. One difference is that negative serum biochemical test results can reduce the risk much more than can normal sonographic findings. Also, biochemical testing is more widely available than high-quality sonography.
It now seems clear that a combined risk estimate using both sonography and biochemical testing will be more effective than either alone. A combined risk would also be less confusing than competing results from each. To date, however, few studies have evaluated the effectiveness of combining sonography and biochemical screening in the second trimester, 136, 137 even though a large number of reports have addressed this combined risk for the first trimester. Roberts and colleagues 138 found that sonography improved detection over that of second-trimester biochemical screening alone from 65% to 80%. Bahado-Singh et al 139 have also shown that incorporation of humerus length and nuchal thickness significantly improves the receiver operator curves of biochemical risk assessment alone. Addition of inhibin to the standard triple-marker test would further increase second-trimester detection of trisomy 21 to 75% on the basis of biochemical screening alone. 140, 141 Optimal sonographic risk assessment will require computer calculations using risk estimates from multiple-of-the-median data from specific measurements (e.g., nuchal thickening and limb length).
In another development, urinary biochemical markers may also prove to be effective in the detection of trisomy 21. Bahado-Singh and colleagues 142 have reported that urinary hyperglycosylated human chorionic gonadotropin (hCG) is superior to the 3 analytes of the triple-marker screen. In 1 study, urine hyperglycosylated hCG was combined with urine β-core fragment serum α-fetoprotein and maternal age to yield a detection rate of 96% with a 5% false-positive rate or 94% sensitivity with a 3% false-positive rate. 143 Incorporation of sonographic biometric measurements with urinary analytes further improves screening performance. Using sonographic measurements of humeral length and nuchal thickness combined with hyperglycosylated hCG, Bahado-Singh et al 144 found a 91.3% detection rate with a 3.2% false-positive rate. The area under the receiver operator curve was 0.986 (P < .001), and that combination was superior to hyperglycosylated hCG plus age alone or any other second-trimester screening protocol.
The Future
First-trimester nuchal translucency screening and biochemical markers have proved to be effective for detection of fetal aneuploidy. 145 At this time, it remains uncertain whether firsttrimester screening is more effective than second-trimester screening and what the ultimate role of second-trimester screening will be. Wald et al 146 have proposed that the combination of first-trimester nuchal translucency screening with both first-and second-trimester biochemical screening might be able to achieve 85% sensitivity for trisomy 21 with only a 1% false-positive rate. If validated clinically, this approach would significantly lower the predictive value of second-trimester sonographic markers. 147, 148 On the other hand, Bahado-Singh and coworkers 139, 144 have shown that sonographic markers can also be correlated with second-trimester biochemical markers to provide similar high detection rates. Only time will tell whether sonographic markers associated with aneuploidy during the second trimester will ultimately have the same interest they do today.
